MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
13.48
+0.83
+6.56%
Closed 16:44 02/09 EST
OPEN
12.65
PREV CLOSE
12.65
HIGH
13.58
LOW
12.60
VOLUME
104.91K
TURNOVER
--
52 WEEK HIGH
19.58
52 WEEK LOW
4.880
MARKET CAP
293.50M
P/E (TTM)
-5.3283
1D
5D
1M
3M
1Y
5Y
1D
Aardvark Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 20h ago
HC Wainwright & Co. Reiterates Buy on Aardvark Therapeutics, Maintains $40 Price Target
Benzinga · 20h ago
Weekly Report: what happened at AARD last week (0202-0206)?
Weekly Report · 22h ago
Weekly Report: what happened at AARD last week (0126-0130)?
Weekly Report · 02/02 10:35
AARDVARK THERAPEUTICS INC <AARD.O>: B. RILEY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $32
Reuters · 01/28 13:03
Aardvark Therapeutics initiated with a Buy at B. Riley
TipRanks · 01/28 09:55
U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth
Reuters · 01/28 07:23
Weekly Report: what happened at AARD last week (0119-0123)?
Weekly Report · 01/26 10:35
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.